Santen
Text Size
Listen
Santen Global
  • Patients
  • Healthcare Professionals
  • Careers
  • Investors
Listen

Tap on the left to use.

  • Who We Are
    Message
    Message from the CEO
    CORE PRINCIPLE / WORLD VISION
    CORE PRINCIPLE / WORLD VISION
    VALUES
    VALUES
    History
    History of Santen
    Corporate Executives
    Corporate Executives
    Corporate Governance
    Corporate Governance
    Policies
    Policies and Statements
    Company Infomation
    Overview / Map
    Global Operation
  • What We Do
    Santen 2030
    Santen 2030
    Medium-term Management Plan
    Efforts to Enhance Patients' Satisfaction
    Efforts to Enhance Product Safety
    Efforts to Enhance Product Usability
    Efforts to Address Untreated Patients
    Research & Development
    Research & Development
    The Ophthalmic Product Process: R&D
    Partnering
    Santen's Partnership
    Our Partners
    Partnering Contact
    Production
    Production
    Quality Compliance
    The Ophthalmic Production Process: Production
    Sales & Marketing
    Sales & Marketing
  • Our Stories
  • Sustainability
    Sustainability at Santen
    Sustainability at Santen
    Social
    Access to Healthcare
    Research & Development in Ophthalmology
    Product Quality & Safety
    Supply Chain
    Human Rights
    Talent
    Digital Transformation (DX)
    Governance
    Corporate Governance
    Compliance
    Ethical Marketing
    Risk Management
    Environment​
    Environmental initiatives
    Measures against Climate Change
    Environmental Load Reduction
    Disclosures Based on the TCFD Recommendations
    Inclusion
    Inclusive Society Santen Promotes
    Inclusion Starting from Blind Football
    Together with Society
    With Employees
    Related Information
    Participating in the UN Global Compact
    Social Contribution Activities
    Stakeholder Engagement
    Environment Data (up-to-date)
    Social Data (up-to-date)
    Governance Data (up-to-date)
    GRI Standards Content Index
    Sustainability Library
    External Assessment
  • News
    News
    Show All
    Press Release
    IR News
    Information
  1. HOME
  2. News
  3. 2023
  4. Press Release

2023 Press Release

RSS

Press Release

09.20.2023 Revision of Full-Year Earnings Forecasts
09.13.2023 Santen Publishes its Annual Integrated Report “Santen Report 2023”
09.04.2023 Notice Regarding Implementation of an Early Retirement Program
07.19.2023 Santen Agrees to Licensing Agreements and Asset Transfer for its Pharmaceutical Products in North America
06.28.2023 Notice of Corporate Officer Changes
05.11.2023 Notice of Board of Director and Corporate Auditor Nominations
04.13.2023 Santen Announces New Medium-Term Management Plan (FY2023-FY2025)
03.27.2023 Santen Files for Manufacturing and Marketing Approval for STN1011402 (Epinastine Hydrochloride) Ophthalmic Cream in Japan - Applied once daily to periocular area, new formulation for treatment of allergic conjunctivitis-
03.01.2023 Notice of Corporate Officer Change
02.08.2023 Santen Announces China NMPA Acceptance of STN1011101 Marketing Authorization Application in Patients with Open-Angle Glaucoma or Increased Intraocular Eye Pressure
 
2022 PR News
2019 PR News
2021 PR News
2018 PR News
2020 PR News
2017 PR News

Official SNS

Twitter LinkedIn YouTube
  • Accessibility
  • Terms of Use
  • Privacy Policy
  • Contact
Copyright © 2023 Santen Pharmaceutical Co., Ltd.
All Rights Reserved